Management of Persistent Epistaxis Using Floseal Hemostatic Matrix vs. traditional nasal packing: a prospective randomized control trial

Table 4 Summary of baseline demographic and clinical characteristics comparing treatment (Floseal® (Baxter, USA)) to control (traditional packing methods)

	Treatment (Floseal) (N = 13)	Control (N = 13)	Z-score	p-value^a,b
Age	59.0	55.1	0.5128	0. 6101^a
Gender (Male)	8 (61.5%)	6 (46.2%)	NA	0.6951^b
ASA	2 (15.4%)	3 (23.1%)	NA	1.000^b
CCI	2.3	2.3	−0.1282	0.8966^a

^a α = 0.05, significant results in bold using unpaired Mann-Whitney U test, CCI Charlson Comorbidity Index, ASA Aspirin 81 mg po daily
^b α = 0.05, significant results in bold using Fisher’s exact test

ISSN: 1916-0216